Deals, Partnering

Agilis Biotherapeutics enters license agreement with the University of South Florida

Posted on 13 May 2015

Tags: , ,

Agilis Biotherapeutics has entered into an exclusive worldwide license agreement with the University of South Florida for the treatment of using gene therapy technology developed by Edwin Weeber, PhD, Director of the Neurobiology of Learning and Memory and Chief Scientific Officer at the USF Health Byrd Alzheimer's Research Institute at the University of South Florida, and one of the world’s foremost AS investigators.

Dr. Weeber and colleagues have developed an innovative gene therapy approach for the treatment of AS and recently published evidence of therapeutic efficacy in the gold standard mouse model.

 

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

Agilis’ collaboration with Dr. Weeber and USF will target the genetic malfunctions of AS using gene therapy to deliver a corrective UBE3a gene to rescue neurological deficits in patients suffering from this rare disease.

Under the terms of the agreement, Agilis will be granted worldwide, exclusive rights to AS gene therapy candidates and related intellectual property.

Print Friendly, PDF & Email

Leave a Reply